APA (7th ed.) Citation

Hamid, O., Thistlethwaite, F., Bendell, J., Plummer, R., Ott, P. A., Sanborn, R. E., . . . Lu, L. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): A first-in-human, dose-finding study. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Hamid, Omid, et al. CX-072 (pacmilimab), a Probody PD-L1 Inhibitor, in Combination with Ipilimumab in Patients with Advanced Solid Tumors (PROCLAIM-CX-072): A First-in-human, Dose-finding Study. BMJ Publishing Group.

MLA (9th ed.) Citation

Hamid, Omid, et al. CX-072 (pacmilimab), a Probody PD-L1 Inhibitor, in Combination with Ipilimumab in Patients with Advanced Solid Tumors (PROCLAIM-CX-072): A First-in-human, Dose-finding Study. BMJ Publishing Group.